摘要
Objective:To synthesize and characterize MCM-41-IL-4 and evaluates its immunomodulatory effect on Raw 264.7 cells.Methods:we synthesized and characterized MCM-41 type mesoporous silica nanoparticles(MSNs)and loaded it with interleukin 4(IL-4);CCK-8 and live and dead staining were used to evaluate Raw 264.7 cell viability;Immunofluorescence was used to study morphology of Raw 264.7 cells;Quantitative real-time polymerase chain reaction(qRT-PCR)were used to study the gene expression of inflammatory factors of Raw 264.7 cells;After the stimulation of human umbilical vein endothelial cells(HUVECs)with MCM-41/RAW 264.7 and MCM-41-IL-4/Raw 264.7 condition medium,the gene expression of angiogenic factor matrix metallopeptidase 9(MMP9)and kinase insert domain protein receptor(VEGF)pathway-related factors from HUVECs was assessed by qRT-PCR.Results:MCM-41-IL-4 can stimulate the proliferation of RAW 264.7 cells;MCM-41-IL-4 can induce RAW 264.7 cells express more the F-actin;MCM-41-IL-4 can increase the expression of M2-related genes transforming growth factor,beta 1(Tgfb1),interleukin 1 receptor antagonist(IL-1ra)and arginase,liver(Arg-1)and decrease the expression of M1-related gene interleukin 6(IL-6);Increased gene expression of MMP9 and platelet derived growth factor receptor alpha(PDGFRα)of HUVECs of MCM-41/Raw 264.7 condition medium was observed.Conclusion:MCM-41-IL-4 can stimulate the proliferation of RAW 264.7 cells,increase the expression of M2-related genes,decrease the expression of M1-related gene and induce the transformation of M2 macrophage which may be used as an immunomodulatory agent for bone tissue engineering applications.
基金
Natural Science Foundation of Jilin province(No.20200201302JC)。
